UBS Group’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

UBS Group’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,500	Closed	-$375	–	11210
2022 Q4	$375	Sell	2,500 -3,921	-61%	-$627	﹤0.01%	10215
2022 Q3	$1K	Sell	6,421 -5,100	-44%	-$748	﹤0.01%	10194
2022 Q2	$1K	Buy	11,521 +1,129	+11%	+$558	﹤0.01%	10118
2022 Q1	$8K	Buy	10,392 +1,850	+22%	+$1.29K	﹤0.01%	8753
2021 Q4	$5K	Buy	8,542 +5,682	+199%	+$5.77K	﹤0.01%	9454
2021 Q3	$3K	Buy	+2,860	New	+$2.98K	﹤0.01%	8886

Other funds holding PEARW

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

DCM

Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

QGA

Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

SRF

Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

UBS Group's PEARW Position: Q1 2023 in Review

UBS Group sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q1 2023, closing a stake of 2,500 shares — an estimated $375 sold.

UBS Group first reported a position in PEARW in Q3 2021 and held it in 6 quarters. The position peaked at $8K in Q1 2022. 33 funds tracked by Wall St. Rank hold PEARW as of Q1 2023.

UBS Group reported no remaining Pear Therapeutics, Inc. Warrant position as of Q1 2023 after selling out during the quarter.
UBS Group sold 2,500 Pear Therapeutics, Inc. Warrant shares in Q1 2023, an estimated $375.
UBS Group first reported a position in Pear Therapeutics, Inc. Warrant in Q3 2021 and held it in 6 quarters.
UBS Group's Pear Therapeutics, Inc. Warrant position peaked at $8K in Q1 2022.
33 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.